EPINEPHRINE BITARTRATE - Generic Drug Details

What are the generic drug sources for epinephrine bitartrate and what is the scope of patent protection?

Epinephrine bitartrate is the generic ingredient in nine branded drugs marketed by Wyeth Cons, 3M, Baxter Hlthcare Corp, Astrazeneca, Dentsply Pharm, Deproco, and Septodont Inc, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for epinephrine bitartrate. One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for EPINEPHRINE BITARTRATE

US Patents:	0
Tradenames:	9
Applicants:	7
NDAs:	10
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	80
Clinical Trials:	5
DailyMed Link:	EPINEPHRINE BITARTRATE at DailyMed

Recent Clinical Trials for EPINEPHRINE BITARTRATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Visarat Palitnonkiat	PHASE1
Siriraj Hospital	PHASE1
King Abdulaziz University	PHASE4

See all EPINEPHRINE BITARTRATE clinical trials

Generic filers with tentative approvals for EPINEPHRINE BITARTRATE

Applicant	Application No.	Strength	Dosage Form
		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	SOLUTION;INTRAVENOUS

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for EPINEPHRINE BITARTRATE

Drug Class	Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists

Anatomical Therapeutic Chemical (ATC) Classes for EPINEPHRINE BITARTRATE

A01AD	Other agents for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

B02BC	Local hemostatics
B02B	VITAMIN K AND OTHER HEMOSTATICS
B02	ANTIHEMORRHAGICS
B	Blood and blood forming organs

C01CA	Adrenergic and dopaminergic agents
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

R01AA	Sympathomimetics, plain
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03AA	Alpha- and beta-adrenoreceptor agonists
R03A	ADRENERGICS, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

S01EA	Sympathomimetics in glaucoma therapy
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for EPINEPHRINE BITARTRATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Deproco	LIGNOSPAN STANDARD	epinephrine bitartrate; lidocaine hydrochloride	INJECTABLE;INJECTION	088390-001	Jan 22, 1985		RX	Yes	Yes
Wyeth Cons	BRONITIN MIST	epinephrine bitartrate	AEROSOL, METERED;INHALATION	016126-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Astrazeneca	CITANEST FORTE	epinephrine bitartrate; prilocaine hydrochloride	INJECTABLE;INJECTION	014763-008	Approved Prior to Jan 1, 1982		DISCN	No	No
Dentsply Pharm	CITANEST FORTE DENTAL	epinephrine bitartrate; prilocaine hydrochloride	INJECTABLE;INJECTION	021383-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes

Market Dynamics and Financial Trajectory for Epinephrine Bitartrate

Last updated: February 14, 2026

Epinephrine bitartrate is a synthetic form of adrenaline used primarily in emergency settings for anaphylaxis, cardiac arrest, and other conditions requiring vasoconstriction. Its market landscape is shaped by regulatory trends, clinical demand, manufacturing capacities, and patent statuses.

Market Overview

Epinephrine remains an essential emergency drug, with the global market valued at approximately USD 1.8 billion in 2022. The compound is available through multiple formulations — injectable solutions, auto-injectors, and topical products.

Demand drivers include:

• Rising prevalence of allergic reactions
• Increasing incidences of cardiac conditions
• Growing emergency medical services (EMS) utilization
• Expanded indications and off-label uses

Market segmentation:

Segment	Key Features	Market Share (2022)
Injectable (hospital)	Used in hospitals for severe allergic reactions and cardiac arrest	60%
Auto-injectors	Patient-administered for at-home emergencies	30%
Topical preparations	Used in dermatology, less common	10%

Regulatory Environment

Major markets like the U.S., EU, and Japan regulate epinephrine as a prescription drug, with auto-injectors (e.g., EpiPen) under stricter oversight due to safety concerns.

Recent regulatory shifts include:

• Stricter quality standards for generic auto-injectors (FDA 2021, EMA 2022)
• Increasing focus on substitution and market competition following patent expirations
• Price control initiatives in EU and U.S. to address affordability

Patent and Market Competition

Patent expirations have led to an increase in generic products, constraining pricing and margins. Notably:

• EpiPen patents expired in 2017 in the U.S., resulting in multiple generic competitors.
• Newer auto-injector devices and biosimilars are entering the market, enhancing competition.
• Companies are investing in alternative formulations to extend product life cycles.

Manufacturing and Supply Chain

Manufacturing involves high-quality standards, often with single-source suppliers for active pharmaceutical ingredients (APIs). Disruptions such as the COVID-19 pandemic highlighted vulnerabilities:

• Supply chain fragility increased prices for APIs.
• Regulatory agencies prioritized supply continuity, impacting manufacturing throughput.

Financial Trajectory

Projected CAGR (Compound Annual Growth Rate):

Year Range	CAGR	Source/Notes
2023-2028	3.5%	Market research by Grand View Research[1]
2028-2033	3.0%	Projected through market analysts

The primary revenue streams are from established markets; expansion depends on:

• Approval of new auto-injector devices
• Off-label indications expanding clinical use
• Market penetration in emerging economies

Recent performances reflect:

• Stable revenues in North America
• Slight growth in Europe due to broader emergency use
• Emerging markets in Asia-Pacific showing initial demand increases

Future Trends and Opportunities

• Development of alternative administration routes to reduce costs and improve safety.
• Product innovations, such as needle-free auto-injectors, to increase patient compliance.
• Regulatory approvals for extended indications, including local anesthesia and vasospasm management.
• Biotech entrants exploring biosimilar versions to reduce prices further.

Challenges and Risks

• Price reductions driven by generic competition.
• Regulatory delays affecting new product launches.
• Supply chain disruptions impacting manufacturing.

Key Takeaways

• The global market for epinephrine bitartrate remains essential, with steady growth driven by clinical demand.
• Patent expirations and regulatory concerns prompt increased competition, reducing margins.
• Innovations in device technology and expanding indications offer pathways for revenue growth.
• Supply chain vulnerabilities pose ongoing risks, especially amid geopolitical or health crises.
• Market expansion is prioritized in emerging economies, although regulatory hurdles persist.

Frequently Asked Questions

1. How does patent expiry affect the epinephrine market?
Patent expiry allows generic manufacturers to produce similar products, increasing competition and reducing prices, which compresses profit margins for branded segments.

2. What are the key regulatory considerations?
Regulatory agencies enforce safety, efficacy, and manufacturing quality standards. Recent trends focus on quality assurance, device safety, and approval processes for biosimilars and new formulations.

3. Are biosimilars entering the epinephrine market?
While biosimilars are more common for biologics, some companies are developing biosimilar auto-injectors or alternative formulations as patent protections expire.

4. What technological innovations are influencing the market?
Needle-free auto-injectors, improved preservative-free formulations, and smart devices with digital tracking are emerging technologies.

5. What is the outlook for emerging markets?
Demand in APAC and Latin America is expected to grow, driven by increasing healthcare infrastructure and awareness. Regulatory frameworks vary, which can impact market entry.

---

References

[1] Grand View Research, "Epinephrine Market Size, Share & Trends Analysis Report," 2022.